Health Science Reports (Sep 2024)

Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta‐analysis

  • Amira Mohamed Taha,
  • Abdelrahman Mohamed Mahmoud,
  • Khaled Abouelmagd,
  • Sara Adel Abdelkader Saed,
  • Basma Badrawy Khalefa,
  • Sangam Shah,
  • Prakasini Satapathy,
  • Muhammad Aaqib Shamim,
  • Sanjit Sah,
  • Hashem Abu Serhan,
  • Suzanne Donovan,
  • Ranjit Sah,
  • Joshuan J. Barboza

DOI
https://doi.org/10.1002/hsr2.70069
Journal volume & issue
Vol. 7, no. 9
pp. n/a – n/a

Abstract

Read online

Abstract Background Mpox infection is a zoonotic illness that resembles smallpox. Vaccination is widely regarded as a vital effective method of preventing mpox, however, there is lack of consensus of effectiveness of a single dose of mpox vaccine in the current 2022–2023 outbreak. We pooled data from real‐world studies to evaluate the efficacy of the JYNNEOS vaccination given as a single dosage. Method We carried out a thorough literature search in PubMed, Web of Science, and Scopus up until August 2023. We estimated the pooled vaccine effectiveness (VE) for mpox using inverse variance method in a random‐effects meta‐analysis. We expressed the results as VE, 95% confidence interval (95% CI), and 95% prediction interval (95% PI) using R v4.3.0. We assessed influence, heterogeneity contribution, and influence of studies using several tests and conducted sensitivity analysis accordingly. We used Doi plot and Luis Furuya‐Kanamori (LFK) index to evaluate publication bias. Results With a total sample size of 35,326 individuals, we involved 11 studies in the meta‐analysis. The VE of a single dose of JYNNEOS vaccine was 78.23% (95% CI: 62.79%–87.27%) by pooling data of 24,784 individuals over seven studies. The findings were heterogenous with a 95% PI of −32.14% to 96.41% depicting the expected range of VE in similar settings. Notably, VE increased to 83.02% (74.62%–88.64%) with a prediction interval of (44.67%–94.79) after sensitivity analysis by leaving out outliers. The results were robust in light of several sensitivity analyses. An asymmetric Doi plot with LFK index of −2.25 showed potential publication bias. Pooled prevalence of mpox infection among vaccinated individuals (breakthrough infection) in six studies was 2.19% (0.37%–5.32%). Conclusion The present findings provide compelling evidence that a single dose of JUNNEOS vaccine can protect recipients from mpox infection. With a 78.23% estimated efficacy rate, the vaccine is thought to be a useful tool in preventing further spread of mpox. However, more research and ongoing surveillance are required to fully understand the reasons behind breakthrough infections and to improve immunization strategies for better protection against mpox.

Keywords